Nemazyn is a hybrid formulation comprised of phytochemical and micronutrient principles. The phytochemicals are derived from the active principles of the neem plant, Azadirachta indica while the micronutrient component provides organic zinc in the form of the highly bioavailable gluconate. Each Nemazyn capsule consists of 25 mg of functional limonoid principles within 250 mg of neem leaf extractives, and 25 mg micronutrient zinc in 174 mg of zinc gluconate. Nemazyn is made from ingredients produced in the US or at overseas facilities that are duly inspected by the US Food and Drug Administration (FDA). The final product is manufactured and quality-checked in the US at FDA-inspected facilities. Kindred Nutraceuticals is fully satisfied with the quality control and compositional consistency of our Nemazyn products.

More than 50 limonoid compounds are present in neem, and it is believed that various combinations of these phytonutrients work together to produce each of the claimed health benefits of the plant. Keeping our processes close to traditional methods of preparation and use, we expect to detect health benefits with our preparation across a range of health modalities. 

Nemazyn is recommended for uses that parallel ethnomedicinal usage of the components, with potentially synergistic effects of the components as presented in this optimized hybrid formulation. Nemazyn components are known to individually express antiviral and antibacterial activities against infectious microbes.  The chief benefit of Nemazyn appears to derive from the shared immunomodulatory activities of zinc and neem phytochemicals. Further, zinc enhances the bioavailability and cellular uptake of neem phytochemicals. We expect that the Nemazyn components would synergistically function to reduce inflammation, boost immune function, support blood sugar control, support blood pressure regulation, and improve metabolic function in human. Nemazyn components have been extensively explored in preclinical or clinical studies with good safety records.  In bringing the individual activities of the components together in one hybrid formulation, Nemazyn is expected to exert powerful additive actions to support the body’s efforts toward maintaining itself in a strong and healthy state.

Nemazyn components may interact with medications containing lithium, antidiabetics or immunosuppressive drugs. As such, persons undergoing treatment with these medications are advised to consult their physician or pharmacist before taking Nemazyn, especially in situations where the outcome is predictable and probably negative (lithium therapy) or positive and probably beneficial (Type II diabetes). Similarly, potential contraceptive effects of neem have been suggested and therefore neem-containing supplements are to be avoided in pregnancy or by persons trying to become pregnant. No carcinogenic or mutagenic effects have been reported, but monitoring for allergic reactions and other possible drug reactions is recommended. Other side effects that may occur include a decrease in blood sugar (especially in hyperglycemic subjects), a decrease in blood pressure (especially in hypertensive subjects), nausea, vomiting, diarrhea, reduction in kidney or liver function, and decreased absorption of some minerals such as copper. Kidney and liver damage and decreased copper absorption are more likely to occur at higher supplement doses and/or longer durations of administration than the levels recommended for use.

Stored in a cool dry environment and away from direct sunlight, Nemazyn capsules can be stable for at least three to five years. The use-by date indicated on the product reflects the third anniversary of the product manufacturing date. We expect that the strategies we have employed in the course of developing Nemazyn Capsule supplements for oral use will be invaluable for informing future natural product development strategies for phytomedicinal and nutraceutical innovations.

References

Monograph Information